OCX - Bathi operasional EBITDA OncoCyte

Absolute EBITDA dynamics reflect market expectations, with the figure holding around . Current quotes are supported by the leadership of OncoCyte Corporation (OCX) in developing non-invasive molecular rapid tests. The business foundation consists of the Determa platform for the early detection of lung pathologies. Production capacities are based on high-load laboratories equipped with modern sequencing and automated sample preparation equipment.

This indicator captures daily cash flow from operating activities, reflecting the actual balance between cash inflows and offsetting liabilities. Analyzing the actual size of operating profit allows for an assessment of the asset restructuring efficiency at OncoCyte Corporation (OCX), however, the low transparency of management's strategy necessitates caution to avoid overpaying for the asset during periods of temporary liquidity growth.